Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐Label, Phase 1 Trial
Open Access
- 22 December 2024
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (5) , 584-593
Abstract
Objective: This work aimed to evaluate the pharmacokinetics, efficacy, and safety of upadacitinib, an oral selective JAK inhibitor, in pediatric patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA).Methods: In an open‐label, phase 1 study (SELECT‐YOUTH), enrolled patients, aged 2 to <18 years with pcJIA, received body weight–based upadacitinib doses using a twice‐daily oral solution or once‐daily extended‐release tablet based on their body weight and ability to swallow tablets. The study included a 7‐day pharmacokinetic assessment, followed by a long‐term efficacy and safety evaluation for up to 156 weeks, including an additional long‐term safety cohort. This interim analysis included available pharmacokinetic and safety data and efficacy data collected through week 48.Results: A total of 57 patients received upadacitinib. The median time to maximum upadacitinib concentration was approximately three hours and one hour for the tablet and oral solution regimens, respectively; the harmonic mean functional half‐life was approximately five hours and two hours, respectively. Juvenile idiopathic arthritis American College of Rheumatology 30, 50, 70, 90, and 100 responses at week 12 were 91.8%, 89.8%, 69.4%, 49.0%, and 32.7%, respectively. Efficacy was generally maintained through week 48, and improvement in additional efficacy end points was also observed. At a median exposure duration of 412 days, 52 of 57 patients reported adverse events; of these, 6 experienced serious adverse events. Adverse events were predominately mild to moderate in severity and consistent with the known safety profile of upadacitinib.Conclusion: This interim analysis demonstrates that the bodyweight‐based dosing regimen of upadacitinib was well tolerated and efficacious in pediatric patients with pcJIA.Keywords
Funding Information
- AbbVie
This publication has 18 references indexed in Scilit:
- Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure–Response Models, and Real‐World Patient DataClinical Pharmacology & Therapeutics, 2024
- Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trialThe Lancet, 2021
- New Medications Are Needed for Children With Juvenile Idiopathic ArthritisArthritis & Rheumatology, 2020
- Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose SelectionClinical Pharmacology & Therapeutics, 2019
- Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical TrialsClinical Pharmacokinetics, 2019
- Long‐Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow‐Up in the Population‐Based Nordic Juvenile Idiopathic Arthritis CohortArthritis Care & Research, 2019
- Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 TrialsClinical Pharmacology in Drug Development, 2018
- Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release TofacitinibClinical Pharmacology & Therapeutics, 2016
- Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid ArthritisClinical Pharmacokinetics, 2016
- Preliminary definition of improvement in juvenile arthritisArthritis & Rheumatism, 1997